IL1B and inflammatory bowel disease: Notably, IL-23 signaling and Th1/Th17 immunity are important mechanisms of intestinal inflammation, and thus IL-1α/IL-1β, the upstream of IL-23 inhibition, can be targeted to treat IBD (41).